Rybelsus 3 mg

Healthcare professionals prescribe Rybelsus 3 mg for the initiation of oral semaglutide treatment in adults with type 2 diabetes. Its uses within a prescribed treatment plan include:

• Starting oral semaglutide treatment

• Allowing the body to adjust during the first 30 days

• Preparing patients for a maintenance semaglutide dose

• Supporting a long-term type 2 diabetes treatment plan

• Complementing diet and regular physical activity

The complete Rybelsus treatment regimen helps improve blood-glucose control in adults with type 2 diabetes. It is also indicated for reducing the risk of serious cardiovascular events in adults with type 2 diabetes who have a high cardiovascular risk.

This cardiovascular benefit applies to the prescribed Rybelsus treatment regimen. It should not be interpreted as a benefit provided by the 3 mg initiation dose alone. People with diabetes and existing cardiovascular concerns can also explore information about heart health medicines.

Rybelsus 3 mg provides a controlled starting point for people beginning oral semaglutide treatment. Its key benefits include:

• Provides a gradual introduction to semaglutide

• Helps the digestive system adjust to treatment

• Reduces the likelihood of severe digestive reactions during initiation

• Offers an oral alternative to injectable GLP-1 treatment

• Supports progression to an effective maintenance dose

• Fits into a once-daily diabetes treatment schedule

• Supports the wider treatment plan for type 2 diabetes

After the initiation stage and transition to the prescribed maintenance dose, semaglutide helps lower fasting and after-meal blood sugar. It can also reduce appetite and food intake in some people.

Rybelsus should be used as one part of a complete diabetes-management plan. Regular blood tests, food choices, physical activity and follow-up appointments remain important throughout treatment.

Semaglutide acts like the naturally occurring GLP-1 hormone released by the digestive system after eating. This hormone helps the body manage blood sugar through several connected actions. Rybelsus:

• Increases insulin release when blood sugar is elevated

• Reduces the release of excess glucagon

• Slows the movement of food from the stomach

• Helps control appetite and food intake

• Reduces fasting and after-meal glucose levels during maintenance treatment

Insulin helps glucose move from the blood into the body’s cells. Glucagon has the opposite effect and tells the liver to release stored glucose. By increasing insulin and reducing unnecessary glucagon release, semaglutide helps maintain more stable blood-sugar levels.

Semaglutide is a protein-based medicine that would normally break down inside the stomach. Rybelsus contains an absorption-enhancing ingredient that protects semaglutide and helps it pass through the stomach lining. This is why the tablet must be taken on an empty stomach and why the instructions concerning water and food are important.

The recommended starting dose is one Rybelsus 3 mg tablet once daily for the first 30 days. This is the initiation stage and is designed to help the body adjust to semaglutide. The 3 mg strength is not considered an effective maintenance dose for controlling blood sugar.

From day 31, the healthcare professional normally increases the dose to 7 mg once daily. Further adjustments depend on blood-glucose results, treatment response and tolerability. Do not continue the 3 mg initiation dose, increase the dose or switch strengths without medical instructions.

Take Rybelsus 3 mg:

• Once daily in the morning

• On an empty stomach

• With up to 120 mL of plain water

• At least 30 minutes before food

• At least 30 minutes before other drinks

• At least 30 minutes before other oral medicines

Swallow the tablet whole. Do not split, crush, chew or dissolve it. Do not take more than one Rybelsus tablet per day or combine several tablets to create a different dose.

If a dose is missed, skip it and take the next scheduled dose the following day. Do not take two tablets to replace the missed dose.

Oral semaglutide formulations with different strength numbers are available in some markets. These products are not automatically interchangeable milligram for milligram. Use only the product and strength written on the prescription.

Common Side Effects: Rybelsus can cause nausea, diarrhoea, abdominal discomfort, reduced appetite, vomiting and constipation. Indigestion, stomach bloating, burping and acid reflux can also occur. Digestive effects are most noticeable when treatment begins or when the dose is increased. Drink enough fluid and contact the healthcare professional if these symptoms persist, become difficult to manage or prevent normal eating and drinking.

Serious Side Effects: Obtain medical attention for persistent or severe abdominal pain, especially when it spreads to the back, because this can indicate pancreatitis. Urgent assessment is also required for sudden vision changes, severe vomiting or diarrhoea, signs of dehydration, reduced urination, symptoms of low blood sugar, yellow skin or eyes, severe upper-abdominal pain, facial or throat swelling, breathing difficulty or another serious allergic reaction. A neck lump, persistent hoarseness or difficulty swallowing should also be medically examined.

Do not start Rybelsus 3 mg without a complete medical review if any of the following apply:

• Personal history of medullary thyroid carcinoma

• Family history of medullary thyroid carcinoma

• Multiple Endocrine Neoplasia syndrome type 2

• Serious allergy to semaglutide

• Allergy to another tablet ingredient

• Pregnancy or planned pregnancy

• Breastfeeding

• Severe gastroparesis

• Type 1 diabetes

• Diabetic ketoacidosis

• Previous pancreatitis

• Serious diabetic eye disease

• Children and adolescents

Semaglutide remains in the body for several weeks. Women planning pregnancy are normally instructed to stop treatment at least two months before trying to conceive. The prescriber should provide an alternative diabetes plan so that blood sugar remains controlled.

Tell the doctor or pharmacist about every prescription medicine, non-prescription product, vitamin and supplement being used. Important interactions include:

• Insulin

• Sulfonylureas

• Levothyroxine

• Warfarin

• Other closely monitored oral medicines

• Other GLP-1 receptor agonists

• Other semaglutide products

Using Rybelsus with insulin or a sulfonylurea can increase the risk of low blood sugar. The healthcare professional can adjust the accompanying diabetes medicine and recommend additional glucose monitoring.

Rybelsus slows stomach emptying and can affect how some oral medicines are absorbed. Take other oral medicines only after the required 30-minute waiting period unless the prescriber provides different instructions. Medicines that require precise blood levels can need additional clinical or laboratory monitoring.

Do not combine Rybelsus with another semaglutide product or GLP-1 receptor agonist unless specifically directed by the treating healthcare professional.

• Keep Rybelsus in its original packaging.

• Store it in a dry place.

• Protect the tablets from moisture.

• Keep the container tightly closed.

• Store according to the temperature stated on the pack.

• Do not transfer tablets into an unlabelled container.

• Keep away from children and pets.

• Do not use damaged or discoloured tablets.

• Check the expiry date before use.

• Dispose of expired tablets through an appropriate medicine-return service.

Official product information for the bottle presentation states storage at 20°C to 25°C, with permitted short-term temperature excursions between 15°C and 30°C. Follow the supplied packaging when local storage instructions differ.